Aysenur Karagoz

Assistant Professor

Bilkent University
Country flagTurkey

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

Year:

2025

The intrinsic stochasticity of patients' response to treatment is a major consideration for clinical decision‐making in radiation therapy. Markov models are powerful tools to capture this stochasticity and render effective treatment decisions. This paper provides an overview of the Markov models for clinical decision analysis in radiation oncology. A comprehensive literature search was conducted within MEDLINE using PubMed, following the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines. Only studies published from 2000 to 2023 were considered. Selected publications were summarized in two categories: (i) studies that compare two (or more) fixed treatment policies using Monte Carlo simulation and (ii) studies that seek an optimal treatment policy through Markov Decision Processes (MDPs). Relevant to the scope of this study, 61 publications were selected for detailed review. The majority of these publications ( n = 56) focused on comparative analysis of two or more fixed treatment policies using Monte Carlo simulation. Classifications based on cancer site, utility measures and the type of sensitivity analysis are presented. Five publications considered MDPs with the aim of computing an optimal treatment policy; a detailed statement of the analysis and results is provided for each work. As an extension of Markov model‐based simulation analysis, MDP offers a flexible framework to identify an optimal treatment policy among a possibly large set of treatment policies. However, the applications of MDPs to oncological decision‐making have been understudied, and the full capacity of this framework to render complex optimal treatment decisions warrants further consideration.

Year:

2024

Purpose To develop a clinical decision-making model for implementation of personalized organ-at-risk (OAR)-sparing adaptive radiation therapy (ART) that balances the costs and clinical benefits of radiation plan adaptations, without limiting the number of re-plannings per patient, and derive optimal policies for head and neck cancer (HNC) radiation therapy. Methods and Materials By leveraging retrospective CT-on-Rails imaging data from 52 HNC patients treated at the University of Texas MD Anderson Cancer Center, a Markov decision process (MDP) model was developed to identify the optimal timing for plan adaptations based on the difference in normal tissue complication probability (ΔNTCP) between the planned and delivered dose to OARs. To capture the trade-off between the costs and clinical benefits of plan adaptations, the end-treatment ΔNTCPs were converted to Quality Adjusted Life Years (QALYs) and, subsequently, to equivalent monetary values, by applying a willingness-to-pay per QALY parameter. Results The optimal policies were derived for 96 combinations of willingness-to-pay per QALY (W) and re-planning cost (RC). The results were validated through a Monte Carlo (MC) simulation analysis for two representative scenarios: (1) W = $200,000 and RC = $1,000; (2) W = $100,000 and RC = $2,000. In Scenario (1), the MDP model’s policy was able to reduce the probability of excessive toxicity, characterized by ΔNTCP ≥ 5%, to zero (down from 0.21 when no re-planning was done) at an average cost of $380 per patient. Under Scenario (2), it reduced the probability of excessive toxicity to 0.02 at an average cost of $520 per patient. Conclusions The MDP model’s policies can significantly improve the treatment toxicity outcomes compared to the current fixed-time (one-size-fits-all) approaches, at a fraction of their costs per patient. This work lays the groundwork for developing an evidence-based and resource-aware workflow for the widespread implementation of ART under limited resources.

Year:

2024

Collaborators (10)

Fatemeh Nosrat

Assistant Professor

University of Florida

UNITED STATES
View details

M. Soheil Hemmati

Assistant Professor

University of Oklahoma

UNITED STATES
View details

Katherine Hutcheson

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Seyedmohammadhossein Hosseinian

Assistant Professor

North Carolina State University

UNITED STATES
View details

Stephen Lai

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Amy Moreno

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Andrew Schaefer

Professor

Rice University

UNITED STATES
View details

Mohamed Naser

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Abdallah Mohamed

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details

Clifton D Fuller

Professor (Tenured)

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details